
Erratum corrigé

Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study

J.L. Pablos, F. Navarro, F.J. Blanco, J.A. Roman-Ivorra, A. Alonso, E. Martín Mola, M. Cantalejo, on behalf of the study investigators, and L. Ercole, N. Rivero

Published in: *Clin Exp Rheumatol* 2019; 37: 437-44.

The authors have brought to our attention that there was an error in the *Results* section on page 440, sub-section *Efficacy findings*, relating to the *p*-value given erroneously as $p=0.007$ instead of $p=0.700$.

The authors would like to point out that the error was due to a typo and does not affect the results or their interpretation and conclusions.

The paragraph containing the error should read as follows:

Switching to TCZ monotherapy was non-inferior to continuing TCZ+MTX for the change in DAS28 at week 28 with and adjusted mean treatment difference of -0.06 (95% CI, -0.40 to 0.27; **$p=0.700$**). As the upper limit of the two-sided 95% CI for the difference between treatment groups was <0.6, TCZ monotherapy demonstrated non-inferiority to combination TCZ+MTX.
